-
- ADME/DMPKDrug Efficacy Testing
- Cerebral Infarct Size Measurement
- Histological Assessment
- Physiological Monitoring
- Behavioral TestingBrain Imaging
- Cerebral Blood Flow Monitoring
- Brain Edema Measurement
- Assessment of Blood-Brain Barrier
- Assessment of Leukocyte-Platelet Aggregates
- Quantitative Analysis of Protein and mRNA Expression
Safety AssessmentIn Vitro Pharmacology- Cell Viability Assay
- Caspase-3 Activity Assay
- In Vitro Neuroinflammatory Models and Assays
- Excitotoxicity In Vitro Assay
- Cell-Based Mitochondrial Function Assay
- In Vitro Oxidative Stress Assay
- Ischemia-Triggered Glutamate Excitotoxicity
- NMDA Receptor-mediated Excitotoxicity
- AMPA Receptor-mediated Excitotoxicity
Molecular Mechanism of Oxidative StressNeuroinflammatory Mechanisms- Ischemia-Reperfusion Injury
Cell Death Mechanism- Autophagy MechanismApoptotic Mechanism
- Ferroptosis Pathways
- Necroptosis Signaling Pathways
Epigenetic Mechanism- Gut Microbiota
- Animal Modeling of Stroke
- Animal Modeling of Ischemic StrokeAnimal Modeling of Hemorrhagic StrokeIn Vitro Modeling of Stroke
- In Vitro Modeling of Ischemic Stroke
- In Vitro Modeling of Hemorrhagic Stroke
- Small-Molecule Antiplatelet DrugsNeuroprotective PeptidesMonoclonal Antibodies for StrokeStem Cell-Based Therapies for StrokeDrug Delivery SystemsInquiry
Nanoparticle-Based Drug Delivery System Development for Stroke
Nanomaterial-based drug delivery systems have attracted extensive interest in preclinical studies due to their targeted drug delivery, controlled drug release, biocompatibility, biodegradability, and low toxicity. To increase the effective concentration of neuroprotective agents in the brain, neuroprotective nanoparticles have been developed as promising delivery systems. Nanomaterials can carry stroke drugs across the blood-brain barrier (BBB) for targeted drug delivery, which in turn releases drugs into tissues and cells damaged by ischemic stroke. Thus, nanomaterials hold great promise for optimizing the treatment of ischemic stroke.
Fig. 1. Advances of nano drug delivery system for the theranostics of ischemic stroke. (Lv et al., 2022) Our Nanoparticle-Based Drug Delivery System Development Services
Ace Therapeutics is a stroke-focused CRO offering customized nanoparticle-based drug delivery system development services. Our experienced team of scientists can help clients develop feasible and effective nanoparticle-based drug delivery systems to deliver stroke drugs across the BBB to targeted ischemic brain regions.
Nanoparticle Design and Synthesis
- We have nanoparticle engineering capabilities to modify nanoparticles to increase the probability and concentration of stroke drugs across the BBB to the ischemic site.
- We carefully optimize the size, surface properties, and loading efficiency of nanoparticles to maximize their BBB permeability.
- We can conjugate targeting ligands to nanoparticles to improve their brain targeting efficiency.
Evaluation of the Encapsulation and Release of Stroke Drugs
- Evaluation of the encapsulation efficiency. The encapsulation efficiency can assessed using several analytical techniques, high performance liquid chromatography (HPLC), UV-vis spectroscopy, Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC).
- In vitro drug release assay: A drug-loaded carrier is immersed in a medium that simulates cerebrospinal fluid, and samples are collected at regular intervals to analyze the concentration of the drug in the solution.
- In vivo evaluation of stroke drug release: The drug delivery system is administered to animal models of stroke, and the distribution and release of the drug delivery system in the body is tracked using magnetic resonance imaging (MRI).
In Vitro and in Vivo Metabolism Studies of Stroke Drugs
- Pharmacokinetic profiles
- Brain–blood partition coefficient (BBPC)
- Volume of drug distribution
- Intracerebral half-life
At Ace Therapeutics, we take advanced approaches to the development of nanoparticle-based drug delivery systems. Our comprehensive services combined with cutting-edge technologies make us the partner of choice for pharmaceutical and biotechnology companies seeking to develop innovative treatments for stroke. If you are interested in our services, please do not hesitate to contact us!
Reference- Lv, W., et al. (2022). Advances of nano drug delivery system for the theranostics of ischemic stroke. Journal of nanobiotechnology, 20(1), 248.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket